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patients. A medical team updates the
anticoagulation therapy for each
patient following a uniform protocol
of anticoagulation. In our experience,
the use of anticoagulation in elderly
people is safe, and quality of life is
not negatively influenced by check of
international normalized ratio.
On this basis, we have reported
our results in terms of impact of
PPM (moderate, severe, or absent)
on survival in elderly people receiv-
ing mechanical prostheses implants.
In our series, the incidence of severe
PPM during the follow-up was very
low. The presence of severe or mod-
erate PPM did not influence long-
term outcome, left ventricular mass
regression, and quality of life in
a population of septuagenarians. On
the basis of our experience, we use
isolated aortic valve replacement
with a mechanical prosthesis, which
represents a judicious alternative in
elderly people to bioprosthesis im-
plant.
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I would like to thank the groups from
Naples and Pittsburgh for their interest
in our recent study examining the im-
pact of prosthesis–patient mismatch
(PPM) on long-term survival in pa-
tients greater than 70 years of age. It
is important to note that we did not
specifically investigate the role of
PPM on tissue valve degeneration,
but it is likely to play a role given the
potential impact of pressure gradients
on leaflet durability. However, as dem-
onstrated by Fann and associates from
Stanford,1 age clearly impacts the rate
of structural valve degeneration, such
that even with first- and second-gener-
ation prostheses, freedom from struc-
tural failure at 15 years exceeds 90%
in patients over 70 years of age. It is
our hope that newer prostheses with
anticalcification treatments, low pres-
sure fixation, and better flow character-
istics yielding lower transvalvular
gradients will demonstrate increased
long-term durability, but only time
will tell.
I think we all agree that the popula-
tion is growing older and living longer
across the globe. For example, in the
United States, life expectancy has in-
creased from 67 years for men and 75
years for women in 1970 to 75 years
for men and 80 years for women in
2005,2 a change that would, in and of
itself, shift the crossover age rightward
for recommending a mechanical over
biologic valve during aortic valve
replacement (AVR). At the same
time, however, lifestyle issues, at least
among my patient population, have be-
come increasingly important with the
desire to avoid lifelong warfarin more
appealing than a potential one-time
‘‘AVR-for-life.’’ This has led to an in-
creasing percentage of well-educated
patients in their 50s, 40s, and evenCardiovascular Surgery c September 230s and 20s, selecting bioprosthetic
over mechanical valves, at least in the
aortic position. We do agree that, al-
though a redo AVR in a 40- or 50-
year-old patient carries little risk,
a redo in an 85- or 90-year-old patient
is a much less desirable proposition.
Vicchio and colleagues3 have devel-
oped a well-structured algorithm for
selecting biologic versus mechanical
prostheses in elderly patients, facili-
tated, no doubt, by their institution’s
outpatient anticoagulation monitoring
program, which boasts (appropriately
so) a very low incidence of bleeding
complications in elderly patients.
An additional shortcoming of our
study is that it did not assess the impact
of PPM on functional status or quality of
life. In a previous study from our unit,
we found that quality of life following
AVR in octogenarians, quantified using
the Medical Outcomes Study Short
Form-36, was similar to the age-
matched general population, but we
did not assess the independent impact
of PPM.4 Clearly, there are patients
who will benefit from the presence of
a diminished gradient over time. How-
ever, it remains my contention that, al-
though it is important to avoid PPM in
younger patients by either enlarging
the root or implanting a prosthesis
with favorable flow characteristics, el-
derly patients with limited preoperative
functional status or significant comor-
bidities are better served with a ‘‘get in
and get out’’ approach during AVR.
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a single case of d-transposition of
the great arteries with particularly
complicated coronary anatomy in
which the switch from direct aortic
cannulation to innominate artery can-
nulation through a PTFE conduit
resulted in rapid hemodynamic recov-
ery and separation from ECLS. In
fact, this method of arterial cannula-
tion has since been used for nearly
Pediatrics
University of Virginia School of
Medicine
Surgical Director, Virginia Children’s
Heart Center
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BRACHIOCEPHALIC ARTERY
ACCESS FOR ARTERIAL
CANNULATION: VALUE AND
TECHNICAL ISSUES
To the Editor:
I read with great interest the report
by Roy and colleagues1 on the rapid
resuscitation of an infant with rescue
extracorporeal life support (ECLS)
with simple access through the innom-
inate artery. In their case, the stump of
a 3.0-mm polytetrafluoroethylene
(PTFE) graft anastomosed to the
innominate artery during the initial
stage I Norwood (Sano) procedure
was rapidly recannulated to provide
arterial access for ECLS. This case
provides yet another good example of
the utility, simplicity, and safety of
proximal brachiocephalic artery access
for arterial cannulation. At my institu-
tion, we have used the same strategy
for arterial cannulation during the Nor-
wood procedure for a number of years
and have found it similarly useful in
a number of ways. Importantly, there
have been no technical complications
related to the use of this technique.
Specifically, there have been no early
or late innominate artery stenoses or
occlusions. In fact, the technique has
been so useful that it has been adopted
for many types of cases requiring aortic
work, such as interrupted aortic arch,
Damus–Kaye–Stansel, coarctation and
ventricular septal defect.
I also suspect that this technique
may be of further use in cases in
which transverse aortic size is border-
line and coronary perfusion could be
compromised by direct aortic cannula-
tion. At our institution, we have had
all arterial switch procedures, with
no mortality and no use of ECLS in
a small series of patients. I and my
colleagues have recently set out to in-
vestigate scientifically whether there
is some benefit to this method of can-
nulation in neonates with regard to
coronary perfusion.
I have a few technical questions for
Roy and colleagues regarding the use
of this technique. First, what is the
ultimate fate of the PTFE when the
chest is closed? How long a segment
do you ultimately leave in the chest
when it is closed? Do you allow the
PTFE to lie on top of the innominate
vein or tuck it in underneath the vein,
next to the aorta? At my institution,
we have been concerned about the
possibility of creating a scissoring
effect on the vein between the PTFE
and the aorta and thus have tucked it
beneath the vein but still worry about
vein occlusion. Additionally, what
steps do you take to clear the PTFE
of clot and debris before rapid cannu-
lation? We attempt to avoid the
formation of clot by multiply clipping
the graft proximally and distally.
Finally, has your group ever consid-
ered using a slightly larger PTFE graft
and reusing it later for the Glenn pro-
cedure if cardiopulmonary bypass is
necessary?
I greatly appreciate this short report
by Roy and colleagues1 regarding this
extremely useful technique. I not only
congratulate them on the survival of
their patient but also applaud the dis-
semination of information with so
much practical importance.
Benjamin B. Peeler, MD
Associate Professor of Surgery and
corporeal life support rescue in patients undergoing
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Reply to the Editor:
We appreciate your comments and
agree that innominate artery cannulation
facilitates aortic arch surgery in the
newborn and may be useful with other
neonatal cardiac repairs, especially
when the ascending aorta is diminutive.
We typically use delayed sternal
closure after stage 1 repair of the hypo-
plastic left heart and trim the graft to
about 4 cm in length after clipping
the proximal end immediately adjacent
to the innominate artery (see Figure 1
in our article1).The graft is anasto-
mosed to the innominate artery cepha-
lad to the innominate vein and sits in
the upper mediastinum, well above
the vein. At the time of delayed sternal
closure, the graft is trimmed to within
several millimeters of the occluding
clips.
If emergency cannulation for extra-
corporeal life support is required, the
shunt is stripped with forceps and
then flushed with heparinized saline
with the proximal clips in place. The
clips are then removed and retrograde
flow through the shunt established.
An 8F BioMedicus cannula (Med-
tronic BioMedicus, Eden Prairie,
Minn) is then inserted in the graft and
secured with 2-0 silk, before connec-
tion to the extracorporeal life support
circuit.
We have not used the same graft for
cannulation at the time of the cavopul-
monary shunt and prefer direct aortic
cannulation.
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